Topic: manufacturing plant
Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.
Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin.
WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.
FDA inspectors have cited a Dr. Reddy's API manufacturing facility which they said was not thoroughly investigating customer complaints.
Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.
Sun Pharmaceutical has struggled to meet FDA expectations for the manufacturing lines at its key launch plant in Halol, India. The struggles continue.
Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.
Athenex has voluntarily suspended production at its Chongqing, China, API facility in the wake of explosions earlier this year.
KriGen Pharmaceuticals plans to build a $7 million facility in Lillington, North Carolina.
CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.